Clinical Research of Autologous Hematopoietic Stem Cell Transplantation for Hematological Malignancies and Solid Tumors
| العنوان: | Clinical Research of Autologous Hematopoietic Stem Cell Transplantation for Hematological Malignancies and Solid Tumors |
|---|---|
| المؤلفون: | Donghua Zhang, Huo Tan, Wei Huang, Cheng-zhi Zhou, Zhenqian Huang, Jie-xia Zhang, Dan Liu, Wenli Liu, Huan-zhu Zhang |
| المصدر: | Blood. 106:5475-5475 |
| بيانات النشر: | American Society of Hematology, 2005. |
| سنة النشر: | 2005 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Cyclophosphamide, business.industry, medicine.medical_treatment, Immunology, Cell Biology, Hematology, Hematopoietic stem cell transplantation, Total body irradiation, medicine.disease, Biochemistry, Surgery, Transplantation, Leukemia, hemic and lymphatic diseases, Internal medicine, medicine, business, Etoposide, Multiple myeloma, medicine.drug, Chronic myelogenous leukemia |
| الوصف: | Objective: To evaluate the therapeutic effect of autologous hematopoietic stem cell transplantation (AHSCT) on hematological malignancies and solid tumors. Methods: 20 patients with median age of 33.4±11.3 (18–50) years received AHSCT, 7 of them were acute non-lymphoblastic leukemias (ANLL)(CR1 5, CR2 1, refractory/relapse 1), 2 were acute lymphoblastic leukemia (ALL)(CR1 2), 1 was chronic myelogenous leukemia (CML-CP2), 1 was chronic lymphoblastic leukemia(CLL-NR), 6 were malignant lymphoma (CR1 2, CR2 2, NR 2), 1 was multiple myeloma, 1 was breast cancer relapsed after resection 10 years and lung and bone metastases, 1 was small cell lung cancer. 2 or 3 of following agents: Cytarabine(Ara-C)3–4g/m2, Cyclophosphamide (CTX) 4–6g/m2, Etoposide (VP-16) 0.5–1.0g/m2, Semustine (me-CCNU) 300mg/m2, Melphala n(Mel) 140mg/m2, Thiotep a (TSPA) 600mg/m2, Carboplatin (CBP) 1.0g/m2, were combined as conditioning regimen in all patients. Among them 2 patients with ALL accepted additional total body irradiation (TBI). Results: All the patients have reconstituted bone marrow hematopoiesis after transplantation. None of them had the transplantation-related mortality. Among 20 cases, 15 achieved disease free survival (DFS) follow-up 36.5(2–106) months. Conclusion: AHSCT might represent an effective approach for the treatment of some patients with chemosensitive solid tumor who are complete remission or part remission. Without compatible donors, patients with leukemia and malignant lymphoma at CR1 stage could receive AHSCT to reduce relapse and increase disease-free survival. It is suggest that have a obvious survival benefit from AHSCT. |
| تدمد: | 1528-0020 0006-4971 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::685d3e3bbc68613f775eafa0ff89d56f https://doi.org/10.1182/blood.v106.11.5475.5475 |
| رقم الأكسشن: | edsair.doi...........685d3e3bbc68613f775eafa0ff89d56f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|